Online inquiry

IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8029MR)

This product GTTS-WQ8029MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets F gene. The antibody can be applied in Respiratory Syncytial Virus (RSV) infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID P03420
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8029MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7066MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ12295MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ1930MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGN 150998
GTTS-WQ4171MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ4899MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ13378MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PR-1498487
GTTS-WQ2682MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ15907MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XOMA 052
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW